Mga Batayang Estadistika
| LEI | 549300G2IVCMC2TJDW72 |
| CIK | 834365 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioLife Solutions, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2025 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Second Quarter 2025 Financial Results Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjus |
|
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| July 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only ( |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (As Permitted by Ru |
|
| May 8, 2025 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2025 Financial Results Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. |
|
| March 24, 2025 |
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair BOTHELL, Wash. (March 18, 2025) – BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therap |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2025 |
Amended Employment Agreement dated June 1, 2023 between the Company and Todd Berard (filed herewith) berardtamendedandrestat Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| March 3, 2025 |
Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| March 3, 2025 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted |
|
| March 3, 2025 |
List of the Company’s Subsidiaries SUBSIDIARIES OF THE REGISTRANT Subsidiaries Place of Incorporation SAVSU Technologies, Inc. Delaware Sexton Biotechnologies, Inc. Delaware |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission F |
|
| March 3, 2025 |
Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| March 3, 2025 |
Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| March 3, 2025 |
DESCRIPTION OF BIOLIFE SOLUTIONS, INC.’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioLife Solutions, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, the Company’s common stock, par value $0.001 per share (“Common Stock”). The following is a description of the material terms and pro |
|
| March 3, 2025 |
BioLife Solutions, Inc. Incentive-based compensation recovery policy (filed herewith) 507226237.3 BIOLIFE SOLUTIONS, INC. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of this BioLife Solutions, Inc. (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to com |
|
| March 3, 2025 |
montevillaleaseamendmen TWELFTH AMENDMENT TO LEASE THIS TWELFTH AMENDMENT TO LEASE (this “Twelfth Amendment”) is made as of June 2024 (the "Effective Date"), by and between ARE-SEATTLE NO. |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| March 3, 2025 |
FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT (“Amendment”) is an agreement made between BioLife Solutions, Inc. |
|
| March 3, 2025 |
woodinvillelease9132022 |
|
| March 3, 2025 |
BioLife Solutions, Inc. Insider Trading Compliance Manual In order to take an active role in the prevention of insider trading violations by its officers, directors, employees, consultants, attorneys, advisors and other related individuals, the Board of Directors (the “Board”) of BioLife Solutions, Inc., a Delaware corporation (the “Company”), has adopted the policies and procedures described in t |
|
| March 3, 2025 | ||
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| January 13, 2025 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| December 20, 2024 |
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors EX-99.1 2 electionofthuntpressrelease.htm EX-99.1 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Appoints Tony J. Hunt to its Board of Directors BOTHELL, Wash. (December 16, 2024) – BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2024 |
Execution Version STOCK PURCHASE AGREEMENT among ARCTIC SOLUTIONS, INC., as the Company, BIOLIFE SOLUTIONS, INC., as the Seller, and STANDEX INTERNATIONAL CORPORATION, as the Buyer Dated as of November 14, 2024 i TABLE OF CONTENTS Page ARTICLE I DEFINITIONS ............................................................................................................1 Section 1.1 Certain Defined Term |
|
| November 20, 2024 |
Unaudited Pro Forma Condensed Consolidated Financial Information 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com Unaudited Pro Forma Condensed Consolidated Financial Information Effective as of November 14, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company” or "BioLife"), entered into a Stock Purchase Agreement (the “Purchase Agreement”), by and among the Company, Stand |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Consent and Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 11th day of November, 2024, by and among (a) SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (“Bank”) and (b)(i) BIOLIFE SOLUTIONS, INC. |
|
| November 12, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Third Quarter 2024 Financial Results Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adj |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
Amended and Restated Bylaws of BioLife Solutions, Inc. 507324348.3 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOLIFE SOLUTIONS, INC. Section 1. Law, Certificate of Incorporation and Bylaws 1.1. These Bylaws are subject to the certificate of incorporation of Biolife Solutions, Inc. (the “Corporation” and such certificate of incorporation, the “Certificate of Incorporation”). In these Bylaws (as amended, the “Bylaws”), references to law, the certificat |
|
| November 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| November 12, 2024 |
507324348.3 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOLIFE SOLUTIONS, INC. Section 1. Law, Certificate of Incorporation and Bylaws 1.1. These Bylaws are subject to the certificate of incorporation of Biolife Solutions, Inc. (the “Corporation” and such certificate of incorporation, the “Certificate of Incorporation”). In these Bylaws (as amended, the “Bylaws”), references to law, the certificat |
|
| November 12, 2024 |
STOCK PURCHASE AGREEMENT by and among SUBZERO PURCHASER CORP., a Delaware corporation SCISAFE, INC., a Delaware corporation, SCISAFE, INC., a New Jersey corporation, and BIOLIFE SOLUTIONS, INC., a Delaware corporation Dated as of November 12, 2024 TABLE OF CONTENTS ARTICLE I DEFINITIONS ........................................................................................................ 1 Secti |
|
| November 12, 2024 |
Unaudited Pro Forma Condensed Consolidated Financial Information 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com Unaudited Pro Forma Condensed Consolidated Financial Information Effective as of November 12, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company” or "BioLife"), completed the sale of all of the issued and outstanding common stock of SciSafe, Holdings, Inc., a |
|
| November 8, 2024 |
BLFS / BioLife Solutions, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioLife Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 09062W204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 8, 2024 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| August 9, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Second Quarter 2024 Financial Results Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 mil |
|
| August 9, 2024 |
Exhibit 2.1 - 1 - STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this "Agreement") is entered into as of April 17, 2024, by and between BioLife Solutions, Inc., a Delaware corporation ("Seller") and GCI Holdings Company, LLC, an Ohio limited liability company ("Buyer"). RECITALS A. Seller owns all of the issued and outstanding shares of common stock (collectively, the "Shares") of Global |
|
| August 9, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***] CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Consent and Second Amendment to Loan and Security Agreement |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| August 8, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Second Quarter 2024 Financial Results Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 mil |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only ( |
|
| June 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only ( |
|
| May 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| May 9, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2024 Financial Results Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freez |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 23, 2024 |
Exhibit 2.1 - 1 - STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this "Agreement") is entered into as of April 17, 2024, by and between BioLife Solutions, Inc., a Delaware corporation ("Seller") and GCI Holdings Company, LLC, an Ohio limited liability company ("Buyer"). RECITALS A. Seller owns all of the issued and outstanding shares of common stock (collectively, the "Shares") of Global |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| April 23, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***] CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Consent and Second Amendment to Loan and Security Agreement |
|
| April 23, 2024 |
Unaudited Pro Forma Condensed Consolidated Financial Information 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com Unaudited Pro Forma Condensed Consolidated Financial Information Effective as of April 17, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company” or "BioLife"), completed the sale of all of the issued and outstanding common stock of Global Cooling, Inc., a Delawa |
|
| April 18, 2024 |
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Announces the Divestiture of its Stirling Freezer Business BOTHELL, Wash. (April 18, 2024) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of bioproduction products and services for the cell and gene the |
|
| April 18, 2024 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| February 29, 2024 |
List of the Company’s Subsidiaries SUBSIDIARIES OF THE REGISTRANT Subsidiaries Place of Incorporation SAVSU Technologies, Inc. Delaware Arctic Solutions, Inc. dba Custom Biogenic Systems Delaware SciSafe Holdings, Inc. Delaware Global Cooling, Inc. Delaware Sexton Biotechnologies, Inc. Delaware BioLife B.V. Netherlands |
|
| February 29, 2024 |
between the Company and Todd Berard ( Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
between the Company and Geraint Phillips (filed herewith) Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
DESCRIPTION OF BIOLIFE SOLUTIONS, INC.’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BioLife Solutions, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, the Company’s common stock, par value $0.001 per share (“Common Stock”). The following is a description of the material terms and pro |
|
| February 29, 2024 |
Non-Employee Director Grant 1 BIOLIFE SOLUTIONS, INC. 2023 OMNIBUS PERFORMANCE INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT RESTRICTED STOCK UNIT AWARD GRANT NOTICE (FOR NON-EMPLOYEE DIRECTORS) BioLife Solutions, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), pursuant to its 2023 Omnibus Performance Incentive Plan (the “Plan”), hereby grants to the i |
|
| February 29, 2024 |
June 1, 2023 between the Company and Karen Foster (filed herewith) Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
between the Company and Sarah Aebersold ( Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
Employee and Executive Form RSU Grant BIOLIFE SOLUTIONS, INC. 2023 OMNIBUS PERFORMANCE INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT RESTRICTED STOCK UNIT AWARD GRANT NOTICE BioLife Solutions, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), pursuant to its 2023 Omnibus Performance Incentive Plan (the “Plan”), hereby grants to the individual whose name |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| February 29, 2024 |
Page 1 of 21 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and pos |
|
| February 29, 2024 |
BioLife Solutions, Inc. Incentive-based compensation recovery policy 507226237.3 BIOLIFE SOLUTIONS, INC. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of this BioLife Solutions, Inc. (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to com |
|
| February 29, 2024 |
29. Notice. Wherever this Lease requires notice to be served on the Tenant or ACEnet, notice shall be sufficient if by actual delivery or if mailed by first class mail with postage fully prepaid to the following address and persons: To ACEnet: ACEnet, Inc. 94 Columbus Road Athens, Ohio 45701 To the Tenant: Global Cooling, Inc. 6000 Poston Road Athens, Ohio 45701 30. Non-discrimination. The Tenant |
|
| February 29, 2024 |
WAIVER AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This Waiver and First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 26th day of February, 2024, by and among (a) SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (“Bank”) and (b)(i) BIOLIFE SOLUTIONS, INC. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| February 29, 2024 |
Amended Employment Agreement dated 1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (‘‘Agreement”) is made between BioLife Solutions Inc. |
|
| February 29, 2024 |
between the Company and Aby Mathew ( FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT (“Amendment”) is an agreement made between BioLife Solutions, Inc. |
|
| February 13, 2024 |
BLFS / BioLife Solutions, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: BioLife Solutions Inc Title of Class of Securities: Common Stock CUSIP Number: 09062W204 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 24, 2024 |
BLFS / BioLife Solutions, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 BLFSSC13GA12024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) BIOLIFE SOLUTIONS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09062W204 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the ap |
|
| January 8, 2024 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | 425.402.1433 fax | BioLifeSolutions.com BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. (January 8, 2024) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”) |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| November 30, 2023 |
BIOLIFE SOLUTIONS, INC. 3303 Monte Villa Parkway, Suite 310 Bothell, Washington, 98021 BIOLIFE SOLUTIONS, INC. 3303 Monte Villa Parkway, Suite 310 Bothell, Washington, 98021 November 30, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioLife Solutions, Inc. Registration Statement on Form S-3 File No. 333-275645 Request for Acceleration Acceleration Request Request Date: December 4, 2023 Request Tim |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023. As filed with the Securities and Exchange Commission on November 30, 2023. Registration No. 333-275645 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3076866 (State or other jurisdiction |
|
| November 30, 2023 |
BIOLIFE SOLUTIONS, INC. 3303 Monte Villa Parkway, Suite 310 Bothell, Washington, 98021 BIOLIFE SOLUTIONS, INC. 3303 Monte Villa Parkway, Suite 310 Bothell, Washington, 98021 November 30, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioLife Solutions, Inc. Registration Statement on Form S-3 File No. 333-275646 Request for Acceleration Acceleration Request Request Date: December 4, 2023 Request Tim |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023. As filed with the Securities and Exchange Commission on November 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3076866 (State or other jurisdiction of incorporation or organization) (I.R |
|
| November 17, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BioLife Solutions, Inc. |
|
| November 17, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) BioLife Solutions, Inc. |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023. As filed with the Securities and Exchange Commission on November 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3076866 (State or other jurisdiction of incorporation or organization) (I.R |
|
| November 17, 2023 |
Exhibit 4.4 BIOLIFE SOLUTIONS, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4(a) 313(b) 5.4(b) 313(c) 5.4(b) (1) This Cross-Reference Table does not constitute part of the Indenture and sha |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Third Quarter 2023 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (November 9, 2023) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading supplier of biopreservation media and other cell processing too |
|
| October 24, 2023 |
BLFS / Biolife Solutions Inc / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| October 23, 2023 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023 Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 re |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| October 23, 2023 |
1 SEPARATION, RELEASE OF CLAIMS AND CONSULTING AGREEMENT This Separation, Release of Claims and Consulting Agreement (“Agreement”) is dated as of this 19th day of October 2023, by and between Michael Rice, his marital community, heirs, and assigns (hereinafter “Employee”), and BioLife Solutions Inc. |
|
| October 23, 2023 |
Page 1 of 12 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”), dated October 19, 2023, is made between BioLife Solutions Inc. |
|
| October 19, 2023 |
EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 19, 2023, between BioLife Solutions, Inc. |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| October 19, 2023 |
EXECUTION VERSION BIOLIFE SOLUTIONS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 19, 2023, between BioLife Solutions, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set fort |
|
| September 26, 2023 |
BLFS / Biolife Solutions Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOLIFE SOLUTIONS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09062W204 (CUSIP Number) SEPTEMBER 18, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| August 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 31, 2023 |
BioLife Solutions Investor Presentation : August 20231 NASDAQ: BLFS Tooling Up Cell & Gene Therapies Investor Presentation August 2023 BioLife Solutions Investor Presentation : August 20232 Safe Harbor Statement NASDAQ: BLFS Certain statements contained in this presentation are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 16, 2023 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT TERMS This Amendment to Employment Terms (this “Amendment”) is made as of August [], 2023, between BioLife Solutions Inc., a Delaware corporation (the “Company”), and [] (“Executive”). Executive and the Company are sometimes referred to herein as the “parties.” In consideration of the mutual covenants and agreements herein contained, and intending to be legally |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 BioLife Solutions, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36362 94-3076866 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 15, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) BioLife Solutions, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Rules 45 |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 15, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2023 |
BIOLIFE SOLUTIONS, INC. 2023 OMNIBUS PERFORMANCE INCENTIVE PLAN SECTION 1. Purpose. The purpose of this 2023 Omnibus Performance Incentive Plan (the “Plan”) is to enable the Company (as defined below) to grant equity compensation awards and other types of incentive compensation. The Plan is intended to replace the Prior Plan (as defined below), which expired on April 25, 2023, as of the Effective |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| August 8, 2023 |
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only ( |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition Report on Form 10-K ☐Transition Report on Form N |
|
| May 10, 2023 |
Exhibit 99.1 BioLife Solutions Reports First Quarter 2023 Financial Results Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines Conference call begins |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| March 31, 2023 |
List of the Company’s Subsidiaries Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiaries Place of Incorporation SAVSU Technologies, Inc. Delaware Arctic Solutions, Inc. dba Custom Biogenic Systems Delaware SciSafe Holdings, Inc. Delaware Global Cooling, Inc. Delaware Sexton Biotechnologies, Inc. Delaware BioLife B.V. Netherlands |
|
| March 31, 2023 |
Exhibit 10.28 FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO AMENDED EXECUTIVE EMPLOYMENT AGREEMENT (“Amendment”) is an agreement made between BioLife Solutions, Inc., a Delaware corporation (“Employer” or the “Company”), and [NAME] (“Executive”). Executive and the Employer are sometimes referred to herein as the “Parties.” The effective date is January 1, 2023 ( |
|
| March 31, 2023 |
Exhibit 10.26 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made between BioLife Solutions Inc., a Delaware corporation (“Employer” or the “Company”), and Geraint Phillips (“Executive”). Executive and the Company are sometimes referred to herein as the “Parties.” The effective date is November 9, 2021. This Agreement supersedes and replaces all prior e |
|
| March 31, 2023 |
Exhibit 10.12 December 19, 2022 Biolife Solutions 3505/3507 Edison Way Menlo Park, CA, 94025 Re: Rent increases for 2023 for suites 3505/3507 Greetings Biolife Solutions Team, Based on the latest executed lease extension clause 6, it was agreed upon to have a 6% rental rate increase for the 2023 year. There was an option to increase the common area, however, Edison Technology Park has decided to k |
|
| March 23, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition Report on Form 10-K ☐Transition Report on For |
|
| March 16, 2023 |
Exhibit 99.1 BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier Record Q4 2022 revenue of $44.3 million increased 19% over 2021; biopr |
|
| March 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| February 9, 2023 |
BLFS / BioLife Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0414-biolifesolutionsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: BioLife Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 09062W204 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to de |
|
| January 11, 2023 |
BLFS / BioLife Solutions Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 BLFSSC13GA12023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) BIOLIFE SOLUTIONS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09062W204 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the ap |
|
| November 9, 2022 |
Exhibit 10.1 Redactions with respect to certain portions hereof denoted with ?***? LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?). The parties agree as follows: 1 LOAN AND TERMS OF PAYMENT 1.1 Term Loan. (a) Ava |
|
| November 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2022 |
Exhibit 99.1 BioLife Solutions Reports Third Quarter 2022 Financial Results Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from operations of $1.5 million and adjusted EBITDA of $1.4 million Tightens 2022 revenue guidance range reflecting year-over-yea |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commiss |
|
| October 6, 2022 |
Exhibit 99.1 BioLife Solutions Announces COO to Retire and Join Board of Directors Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice President, Global Operations BOTHELL, Wash., October 3, 2022 ?BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of cl |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commiss |
|
| September 12, 2022 |
Exhibit 4.6 Amendment No. 3 to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan This Amendment No. 3 (the ?Amendment?) to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (as amended, the ?Plan?), is made effective as of June 9, 2022 by BioLife Solutions, Inc. (the ?Company?). WITNESSETH: WHEREAS, the Plan was originally |
|
| September 12, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) BioLife Solutions, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Other 2, |
|
| September 12, 2022 |
As filed with the Securities and Exchange Commission on September 12, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 12, 2022 Registration No. |
|
| August 26, 2022 |
Exhibit 99.1 BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash. (August 25, 2022) ? BioLife Solutions, Inc. (Nasdaq: BLFS) (?BioLife? or the ?Company?), a leading developer and supplier of class- |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
Exhibit 99.1 BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and higher organic growth |
|
| June 22, 2022 |
BLFS / BioLife Solutions Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOLIFE SOLUTIONS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09062W204 (CUSIP Number) JUNE 16, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other Jurisdiction of Incorporation) (Commission Fi |
|
| May 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2022 |
Exhibit 99.1 BioLife Solutions Reports First Quarter 2022 Financial Results Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39% Sequential Improvement in Gross Margin a |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only ( |
|
| April 7, 2022 |
EX-16.1 2 ex355769.htm EXHIBIT 16.1 Exhibit 16.1 April 7, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 2, 2022, to be filed by our former client, BioLife Solutions, Inc. We agree with the statements made in response to that Item insofar as they relate |
|
| April 7, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2022 |
Exhibit 10.16 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (the "Amendment") dated this 4th of December, 2018 amends that certain Lease dated July 24, 2007 as amended on November 4, 2008, March 2, 2012, June 15, 2012, November 26, 2012, August 19, 2014 and March 3, 2017 by and between BIOLIFE SOLUTIONS, INC. ("Tenant") and MONTE VILLA FARMS LLC ("Landlord") (the "Lease") in the proje |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| March 31, 2022 |
List of the Company’s Subsidiaries Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiaries Place of Incorporation SAVSU Technologies, Inc. Delaware Arctic Solutions, Inc. dba Custom Biogenic Systems Delaware SciSafe Holdings, Inc. Delaware Global Cooling, Inc. Delaware Sexton Biotechnologies, Inc. Delaware BioLife B.V. Netherlands |
|
| March 31, 2022 |
Exhibit 10.24 Lease Agreement Between Athens County Port Authority (?Landlord?) and Global Cooling Inc. A Delaware Corporation (?Tenant?) ARTICLE ONE: BASIC TERMS This Article One contains the Basic Terms of this Lease between the Landlord and Tenant named below. Other Articles, Sections and Paragraphs of the Lease referred to in this Article One explains and defines the Basic Terms and are to be |
|
| March 31, 2022 |
Exhibit 10.18 NINTH AMENDMENT TO LEASE THIS NINTH AMENDMENT TO LEASE (the ?Amendment?), effective as of November 12, 2020, is entered into by and between Monte Villa Farms LLC (?Landlord?) and BioLife Solutions, Inc. (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease dated July 24, 2007, as the same has been amended by that certain First Amendment to Lease dated November |
|
| March 31, 2022 |
Exhibit 10.26 LEASE THIS LEASE (this "Lease") is executed effective as of October 1, 2019 ("Commencement Date"), by and between Cook Regentec, LLC, an Indiana limited liability company ("Landlord"), and Sexton Biotechnologies, Inc., a Delaware corporation ("Tenant"). ARTICLE 1 - LEASE OF PREMISES Section 1.01. Basic Lease Provisions and Definitions. (a) The "Leased Premises" is described on Exhibi |
|
| March 31, 2022 |
Exhibit 10.21 LEASE 301 Treble Cove Road Billerica, LLC, a Massachusetts limited liability company, as Landlord, and BioLife Solutions, Inc., a Delaware corporation, as Tenant with respect to certain premises containing approximately 26,800 square feet of space at 301 Treble Cove Road in Billerica, Massachusetts TABLE OF CONTENTS Article Page ARTICLE I: BASIC TERMS 1 ARTICLE II: LEASE OF PREMISES |
|
| March 31, 2022 |
Exhibit 10.27 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "Amendment") is made as of the date of last execution hereof by both parties ("Effective Date"), by and between COOK REGENTEC, LLC, an Indiana limited liability company ("Landlord"), and SEXTON BIOTECHNOLOGIES, INC., a Delaware corporation ("Tenant"). RECITALS: A. Landlord and Tenant entered into a certain Lease dated as of |
|
| March 31, 2022 |
Exhibit 10.25 LEASE EXTENSION AGREEMENT To the Lease Agreement Between Athens County Port Authority ("Landlord") and Global Cooling, Inc., A Delaware Corporation ("Tenant'') This Lease Extension is hereby made and entered into by and between the Athens County Port Authority (hereinafter referred to as "Landlord") and Global Cooling, Inc., A Delaware Corporation (hereinafter referred to as "Tenant' |
|
| March 31, 2022 |
Exhibit 10.36 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Troy Wichterman (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is November 4, 2021. This Agreement supersedes and replaces all prior em |
|
| March 31, 2022 |
Exhibit 10.17 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (the "Amendment") dated this 1st of November 2019 amends that certain Lease dated July 24, 2007 as amended on November 4, 2008, March 2, 2012, June 15, 2012, November 26, 2012, August 19, 2014, March 3, 2017 and December 4, 2018 by and between BIOLIFE SOLUTIONS, INC. ("Tenant") and MONTE VILLA FARMS LLC ("Landlord") (the "Lease |
|
| March 31, 2022 |
Exhibit 2.6 AGREEMENT AND PLAN OF MERGER by and among BIOLIFE SOLUTIONS, INC., as the Purchaser, BLFS MERGER SUB, INC., as Merger Sub, FORTIS ADVISORS LLC, in the capacity as the Seller Representative, and SEXTON BIOTECHNOLOGIES, INC., as the Company, Dated as of August 9, 2021 I. MERGER 5 1.1. Merger 5 1.2. Effective Time 5 1.3. Effect of the Merger 5 1.4. Tax Treatment 5 1.5. Certificate of Inco |
|
| March 31, 2022 |
Exhibit 10.23 EXTENSION AND AMENDMENT OF LEASE THIS EXTENSION AND AMENDMENT OF LEASE (?Amendment?) is entered into by and between the EDISON TECHNOLOGY PARK TWO LLC (?Lessor?) and BIOLIFE SOLUTIONS, INC. (?Lessee?) and is effective as of the 4th day of February 2022. Lessor and Lessee are herein collectively referred to as ?Parties.? RECITALS This Amendment is made and entered into on the basis of |
|
| March 31, 2022 |
Exhibit 10.20 ELEVENTH AMENDMENT TO LEASE THIS ELEVENTH AMENDMENT TO LEASE (this ?Eleventh Amendment?) is made as of February 22, 2022, by and between ARE-SEATTLE NO. 38, LLC, a Delaware limited liability company (?Landlord?), and BIOLIFE SOLUTIONS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease dated as of July 24, 2007 (the ?Original Le |
|
| March 31, 2022 |
Exhibit 10.15 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (the "Amendment") dated this 3rd of March. 2017 amends that certain Lease dated July 24, 2007 and amended on November 4, 2008, March 2, 2012, June 15, 2012, November 26. 2012 and August 19, 2014 by and between BIOLIFE SOLUTIONS, INC. ("Tenant'") and MONTE VILLA FARMS LLC ("'Landlord") (the "Lease"') in the project known as "Monte |
|
| March 31, 2022 |
Exhibit 10.22 COMMERCIAL LEASE AND DEPOSIT RECEIPT Received from hereinafter referred to as BioLife Solutions LESSEE, the sum of $11,072.00 (Eleven Thousand and Seventy-Two Dollars) as a deposit which shall belong to Lessor and shall be applied as follows: Total Received Due Rent for unit 3505 & 3507 11,072.00 12/01/2020 Security Deposit 3505 Edison Wav 4,512.00 11/01/2020 Security Deposit 3507 Ed |
|
| March 31, 2022 |
Exhibit 10.33 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Roderick de Greef (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is November 4, 2021. This Agreement supersedes and replaces all prior |
|
| March 31, 2022 |
Exhibit 10.19 TENTH AMENDMENT TO LEASE THIS TENTH AMENDMENT TO LEASE (this "Tenth Amendment") is made as of October 8, 2021, by and between ARE-SEATTLE NO. 38, LLC, a Delaware limited liability company ("Landlord"), and BIOLIFE SOLUTIONS, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are parties to that certain Lease dated as of July 24, 2007, as amended by that certain |
|
| March 18, 2022 |
BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing Exhibit 99.1 BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing BOTHELL, Wash. (March 18, 2022) ? BioLife Solutions, Inc. (Nasdaq: BLFS) (?BioLife? or the ?Company?), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and biopharma markets, announced today that it has received a notice (?Notice |
|
| March 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ?Transition Report on Form 10-K ?Transition Report on Form 20-F ?Transition Report on Form 11-K ?Transition Report on Form 10-K ?Transition Report on For |
|
| February 28, 2022 |
Exhibit 99.1 BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results Record quarterly revenue of $37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64% Record full year revenue of $119.2 million up 148% over 2020, with organic revenue growth of 37% and biopreservation media revenue growth of 39% Initial |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| February 9, 2022 |
BLFS / BioLife Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: BioLife Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 09062W204 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2022 |
EX-99.1 2 ex322487.htm EXHIBIT 99.1 Exhibit 99.1 BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020 Biopreservation Media Revenue of $43 Million Increased 39% Over 2020 BOTHELL, Wash., January 10, 2022—BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader bio |
|
| November 15, 2021 |
Employment Agreement dated November 4, 2021 between the Company and Troy Wichterman (filed herewith) Exhibit 10.1 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Troy Wichterman (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is November 4, 2021. This Agreement supersedes and replaces all prior emp |
|
| November 15, 2021 |
Exhibit 10.2 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Roderick de Greef (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is November 4, 2021. This Agreement supersedes and replaces all prior e |
|
| November 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| November 12, 2021 |
Exhibit 99.1 BioLife Solutions Announces Third Quarter 2021 Financial Results Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue Raises full-year 2021 revenue guidance to $115 to $119 million, reflecting strong demand for proprietary biopreservation media products Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (Novem |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2021 |
BioLife Solutions Announces Executive Management Changes Exhibit 99.1 BioLife Solutions Announces Executive Management Changes BOTHELL, Wash. November 4, 2021 ? BioLife Solutions, Inc. (the ?Company?) (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (?CGT?) and broader biopharma markets, today announced changes to its executive management team, effective immediately. Troy Wichterman, B |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2021 |
BLFS / BioLife Solutions Inc / VILLIGER WALTER - SCHEDULE 13D/A Activist Investment SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) BioLife Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09062W204 (CUSIP Number) Michael Rice, Chief Executive Officer 3303 Monte Villa Parkway, Suite 310 Bothell, Washington 98021 (425) 402-1400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other Jurisdiction of Incorporation) (Commiss |
|
| September 8, 2021 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| September 1, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on September 1, 2021 Registration No. |
|
| August 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| August 13, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2021 |
Exhibit 99.1 BioLife Solutions Announces Second Quarter 2021 Financial Results Total revenue grew 215% over Q2 2020 and 85% over Q1 2021 Organic revenue up 49% over Q2 2020 driven by 45% media revenue growth Full year revenue guidance raised to $108 to $117 million, reflecting expected contribution from Sexton Biotechnologies Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (A |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| July 21, 2021 |
BLFS / BioLife Solutions Inc / VILLIGER WALTER - SCHEDULE 13D/A Activist Investment SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) BioLife Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09062W204 (CUSIP Number) Michael Rice, Chief Executive Officer 3303 Monte Villa Parkway, Suite 310 Bothell, Washington 98021 (425) 402-1400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Octobe |
|
| July 21, 2021 |
BLFS / BioLife Solutions Inc / GIRSCHWEILER THOMAS - SCHEDULE 13D/A Activist Investment SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) BioLife Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09062W204 (CUSIP Number) Michael Rice, Chief Executive Officer & President 3303 Monte Villa Parkway, Suite 310 Bothell, Washington 98021 (425) 402-1400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicat |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other Jurisdiction of Incorporation) (Commission F |
|
| July 7, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 (May 3, 2021) BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation |
|
| July 7, 2021 |
Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.3 Unaudited Pro Forma Condensed Combined Financial Information GCI Merger General Terms and Effects On March 19, 2021, BioLife Solutions, Inc. (the ?Company?), a Delaware corporation, entered into an Agreement and Plan of Merger (the ?Merger Agreement?) with BLFS Merger Subsidiarity, Inc., a Delaware corporation (?Merger Sub?), Global Cooling, Inc., a Delaware corporation (?GCI? or ?Glo |
|
| July 7, 2021 |
Exhibit 99.2 Global Cooling, Inc. and Subsidiary Consolidated Financial Statements March 31, 2021 and 2020 (Unaudited) TABLE OF CONTENTS Consolidated Financial Statements (Unaudited): Balance Sheets as of March 31, 2021 and December 31, 2020 (Unaudited) 1-2 Statements of Operations for the three months ended March 31, 2021 and 2020 (Unaudited) 3 Statements of Stockholders? Equity (Deficit) for the |
|
| July 7, 2021 |
As filed with the Securities and Exchange Commission on July 7, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 7, 2021 Registration No. |
|
| July 7, 2021 |
EX-99.1 3 ex261761.htm EXHIBIT 99.1 Exhibit 99.1 Global Cooling, Inc. and Subsidiary Consolidated Financial Statements December 31, 2020 and 2019 with Independent Auditors’ Report TABLE OF CONTENTS Independent Auditors’ Report 1 Consolidated Financial Statements: Consolidated Balance Sheets 3 - 4 Consolidated Statements of Operations 5 Consolidated Statements of Stockholders’ Equity 6 Consolidated |
|
| July 7, 2021 |
Exhibit 4.5 Amendment No. 2 to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan This Amendment No. 2 (the ?Amendment?) to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (as amended, the ?Plan?), is made effective as of June 18, 2021 by BioLife Solutions, Inc. (the ?Company?). WITNESSETH: WHEREAS, the Plan was originall |
|
| June 24, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 19, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 222437 Prospectus Supplement No. 1 to Reoffer Prospectus of BioLife Solutions, Inc. Up to 4,772,247 Shares of Common Stock under the BioLife Solutions, Inc. Second Amended & Restated 2013 Performance Incentive Plan, the BioLife Solutions, Inc. 1998 Stock Option Plan, as amended, and various Non-Plan Stock Option Agreements This Prospectus Supp |
|
| May 17, 2021 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Maurice ?Dusty? H. Tenney III (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is May 3, 2021 (?Effective Date?). RECITALS A. Employer is in the b |
|
| May 17, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| May 13, 2021 |
Exhibit 99.1 BioLife Solutions Announces First Quarter 2021 Financial Results Achieves record quarterly revenue of $16.8 million, a 39% increase over the prior year and 14% increase over the prior quarter Full year revenue guidance raised to $106 to $115 million reflecting confidence in outlook Additions to leadership team and board position company for continued robust growth serving the cell and |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only ( |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission F |
|
| April 7, 2021 |
Exhibit 99.1 BioLife Solutions Appoints Two New Independent Board Directors Amy DuRoss, CEO at Vineti and Rachel Ellingson, Chief Strategy Officer at Zimmer Biomet BOTHELL, Wash. (April 6, 2021) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, tod |
|
| March 31, 2021 |
Exhibit 10.2 Amendment No. 1 to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan This Amendment No. 1 (the ?Amendment?) to the BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (as amended, the ?Plan?), is made effective as of July 9, 2020 by BioLife Solutions, Inc. (the ?Company?). WITNESSETH: WHEREAS, the Plan was originall |
|
| March 31, 2021 |
List of the Company’s Subsidiaries Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Subsidiaries Place of Incorporation SAVSU Technologies, Inc. Delaware Arctic Solutions, Inc. dba Custom Biogenic Systems Delaware SciSafe Holdings, Inc. Delaware |
|
| March 31, 2021 |
Exhibit 10.17 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Karen Foster (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employment |
|
| March 31, 2021 |
Exhibit 10.18 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Roderick de Greef (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employ |
|
| March 31, 2021 |
Employment Agreement dated January 1, 2021 between the Company and Sarah Aebersold (filed herewith) Exhibit 10.24 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Sarah Aebersold (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is January 1, 2021. RECITALS A. Employer is in the business (the ?Busine |
|
| March 31, 2021 |
Exhibit 10.13 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Todd Berard (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employment a |
|
| March 31, 2021 |
Exhibit 10.25 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Marcus Schulz (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employment |
|
| March 31, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| March 31, 2021 |
Exhibit 10.11 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Michael P. Rice (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employme |
|
| March 31, 2021 |
Exhibit 10.12 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (?Agreement?) is made between BioLife Solutions Inc., a Delaware corporation (?Employer? or the ?Company?), and Aby J. Mathew (?Executive?). Executive and the Company are sometimes referred to herein as the ?Parties.? The effective date is December 1, 2020. This Agreement supersedes and replaces the employment |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| March 25, 2021 |
Exhibit 2.1 Redactions with respect to certain portions hereof are denoted with ?***? AGREEMENT AND PLAN OF MERGER by and among BIOLIFE SOLUTIONS, INC., as the Purchaser, BLFS MERGER SUBSIDIARY INC., as Merger Sub, ALBERT VIERLING AND WILLIAM BAUMEL, in their capacity as Seller Representative, and GLOBAL COOLING, INC., as the Company, Dated as of March 19, 2021 I. MERGER 5 1.1. Merger 5 1.2. Trans |
|
| March 25, 2021 |
Form of Non-Competition Agreement Exhibit 10.2 NON-COMPETITION AND NON-SOLICITATION AGREEMENT THIS NON-COMPETITION AND NON-SOLICITATION AGREEMENT (this ?Agreement?) is being executed and delivered as of March 19, 2021, by the undersigned stockholder of the Company (as defined below) (the ?Subject Party?) in favor of and for the benefit of, BioLife Solutions, Inc., a Delaware corporation (the ?Purchaser?), Global Cooling, Inc., a D |
|
| March 25, 2021 |
EX-10.1 3 ex236749.htm EXHIBIT 10.1 Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made as of March 19, 2021 by and among (i) BioLife Solutions, Inc., a Delaware corporation (the “Purchaser”), (ii) Global Cooling, Inc., a Delaware corporation (the “Company”), and (iii) the undersigned stockholder (“Holder”) of the Company. Any capitalized term used but not defined in thi |
|
| March 22, 2021 |
EX-99.2 3 ex235926.htm EXHIBIT 99.2 Exhibit 99.2 BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger Including Stirling, BioLife’s Q4 2020 Annualized Revenue Totals $115 Million Mid to Long Term Adjusted EBITDA Margin Target of 30% Stirling CEO Dusty Tenney to Join BioLife as President & COO Conference Call Begins at 4:30 p.m. Eastern Time Today BOTHELL, Wash. (March 22, 2021) – |
|
| March 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2021 |
EX-99.1 2 ex235925.htm EXHIBIT 99.1 Exhibit 99.1 BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results Q4 total revenue of $14.7 million increased 78%, full year total revenue of $48.1 million increased 76% Introduces guidance for 2021 total revenue of $101 million to $110 million, up 110% to 129% over 2020 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, W |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2021 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| December 14, 2020 |
Exhibit 99.2 SCISAFE HOLDINGS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) For the nine months ended September 30, 2020 and 2019 SCISAFE HOLDINGS, INC. TABLE OF CONTENTS Page Unaudited Condensed Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019 1 Condensed Consolidated Statements of Income for the nine months ended September |
|
| December 14, 2020 |
Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2020 (October 1, 2020) BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of inco |
|
| December 14, 2020 |
Exhibit 99.3 BioLife Solutions, Inc. Unaudited Pro Forma Condensed Combined Balance Sheets September 30, 2020 (In thousands) Historical Historical Pro Forma Notes Pro Forma BioLife SciSafe Adjustments (1) Combined ASSETS CURRENTASSETS Cash and cash equivalents $ 93,984 $ 1,063 $ (563 ) (a) $ 94,484 Restricted cash in escrow 15,000 - (14,175 ) (b) 825 Accounts receivable, trade, net 6,095 945 - 7,0 |
|
| December 14, 2020 |
Exhibit 99.1 SCISAFE HOLDINGS LIMITED AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS Year ended December 31, 2019 SCISAFE HOLDINGS LIMITED TABLE OF CONTENTS Page Independent Auditor’s Report 1 Consolidated Financial Statements Consolidated Balance Sheet as of December 31, 2019 2 Consolidated Statement of Income for the Year Ended December 31, 2019 3 Consolidated Statement of Stockholders’ Equi |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissi |
|
| November 27, 2020 |
BLFS / BioLife Solutions, Inc. / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. |
|
| November 5, 2020 |
Exhibit 99.1 BioLife Solutions Announces Third Quarter 2020 Financial Results Q3 total revenue of $11.3 million increased 71% over the prior year Three month media revenue up 22% versus 2019 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (November 5, 2020) – BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio o |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commissio |
|
| October 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commission |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2020 BIOLIFE SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36362 94-3076866 (State or other jurisdiction of incorporation) (Commiss |
